Trial · NCT00294554

Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia

NCT00294554, Not applicable, Completed, Johns Hopkins University; results first posted 2017-09-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia. Trials, record NCT00294554. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00294554

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia
NCT number: NCT00294554
Status: Completed
Phases: Not applicable
Enrollment: 20 participants, actual
Lead sponsor: Johns Hopkins University
Conditions: Parkinson's Disease, Cognitive Impairment, Dementia
Interventions: Memantine, Placebo Oral Tablet
First posted: 2006-02-22
Last updated: 2017-09-12
Results first posted: 2017-09-12

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Dementia Rating Scale (DRS) Memory Subscore	change from baseline to 24 weeks	The DRS is comprised of: Attention (ATT, 8 items); Initiation-Perseveration (I-P, 11 items); Construction (CONST, 6 items); Conceptualization (CONCEPT, 6 items); and Memory (MEM, 5 items). For this study, only the memory subscore was used, with score possibilities ranging from 0-5, with 5 meaning memory was perfect, 0 being no ability to recall. A negative score indicates a decrease in memory from baseline to 24 weeks.
Primary	CIBIC-Plus Score	24 weeks	CIBIC-Plus is based upon clinicians' observations of change in the patient's cognitive, functional, and behavioral performance since the beginning of a trial. It relies on both direct examination of the patient and interview of informants. It takes into account a subject's overall function in the cognitive, behavioral and functional activity domains. Scoring is based on an interview with the caregiver and examination of the patient by an independent evaluator, without consulting other information such as cognitive test results. It requires the assessor to consider a number of cognitive, functional, and behavioral areas prior to providing an overall "global" assessment of clinical change. 7-point categorical scale that provides a single global rating of change from baseline.A score of 1 indicates marked improvement;and a score of 7, marked worsening.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Dementia Rating Scale (DRS) Memory Subscore	change from baseline to 24 weeks		units on a scale	MEAN
PRIMARY	CIBIC-Plus Score	24 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Dementia Rating Scale (DRS) Memory Subscore	Active Memantine		1.6	95% Confidence Interval -0.13 to 3.33	units on a scale
Change in Dementia Rating Scale (DRS) Memory Subscore	Placebo Oral Tablet		-1.4	95% Confidence Interval -3.19 to 0.39	units on a scale
CIBIC-Plus Score	Active Memantine	Very Much Improved	1		Participants
CIBIC-Plus Score	Placebo Oral Tablet	Very Much Improved	0		Participants
CIBIC-Plus Score	Active Memantine	Much Improved	5		Participants
CIBIC-Plus Score	Placebo Oral Tablet	Much Improved	2		Participants
CIBIC-Plus Score	Active Memantine	Minimally Improved	2		Participants
CIBIC-Plus Score	Placebo Oral Tablet	Minimally Improved	1		Participants
CIBIC-Plus Score	Active Memantine	No Change	0		Participants
CIBIC-Plus Score	Placebo Oral Tablet	No Change	3		Participants

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Active Memantine	10
Overall Study	STARTED	Placebo Oral Tablet	10
Overall Study	COMPLETED	Active Memantine	10
Overall Study	COMPLETED	Placebo Oral Tablet	8
Overall Study	NOT COMPLETED	Active Memantine	0
Overall Study	NOT COMPLETED	Placebo Oral Tablet	2

Source ClinicalTrials.gov

Adverse events70

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Incident Concentration Difficulties	Nervous system disorders	Active Memantine	0	10	0
other	Incident Concentration Difficulties	Nervous system disorders	Placebo Oral Tablet	1	10	1
other	Incident Fatigue	General disorders	Active Memantine	2	10	2
other	Incident Fatigue	General disorders	Placebo Oral Tablet	0	10	0
other	Incident Sleepiness	General disorders	Active Memantine	2	10	2
other	Incident Sleepiness	General disorders	Placebo Oral Tablet	0	10	0
other	Incident Depression	Psychiatric disorders	Active Memantine	1	10	1
other	Incident Depression	Psychiatric disorders	Placebo Oral Tablet	1	10	1
other	Incident Tension	Psychiatric disorders	Active Memantine	1	10	1
other	Incident Tension	Psychiatric disorders	Placebo Oral Tablet	1	10	1

1 to 10 of 70Source ClinicalTrials.gov

See all 70 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Active Memantine	0	10
Total, all-cause mortality	Placebo Oral Tablet	0	10
Total, other adverse events	Active Memantine	6	10
Total, other adverse events	Placebo Oral Tablet	8	10
Total, serious adverse events	Active Memantine	0	10
Total, serious adverse events	Placebo Oral Tablet	0	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Active Memantine vs Placebo Oral Tablet: deaths from any cause	Trial comparisons
Active Memantine vs Placebo Oral Tablet: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00294554

GET https://conductscience.org/api/trials/v1/NCT00294554/events?page=2

API reference For AI assistants